158 related articles for article (PubMed ID: 11575864)
1. Dynamic and kinetic effects of chronic citalopram treatment in experimental hepatic encephalopathy.
Apelqvist G; Wikell C; Carlsson B; Hjorth S; Bergqvist PB; Ahlner J; Bengtsson F
Clin Neuropharmacol; 2000; 23(6):304-17. PubMed ID: 11575864
[TBL] [Abstract][Full Text] [Related]
2. Effect of citalopram on brain serotonin release in experimental hepatic encephalopathy: implications for thymoleptic drug safety in liver insufficiency.
Bergqvist PB; Wikell C; Hjorth S; Apelqvist G; Bengtsson F
Clin Neuropharmacol; 1997 Dec; 20(6):511-22. PubMed ID: 9403225
[TBL] [Abstract][Full Text] [Related]
3. Altered open-field behavior in experimental chronic hepatic encephalopathy after single venlafaxine and citalopram challenges.
Apelqvist G; Wikell C; Hindfelt B; Bergqvist PB; Andersson G; Bengtsson F
Psychopharmacology (Berl); 1999 Apr; 143(4):408-16. PubMed ID: 10367559
[TBL] [Abstract][Full Text] [Related]
4. Brain monoamine output alterations after a single venlafaxine challenge in experimental hepatic encephalopathy.
Wikell C; Bergqvist PB; Hjorth S; Apelqvist G; Björk H; Bengtsson F
Clin Neuropharmacol; 1998; 21(5):296-306. PubMed ID: 9789710
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetic and pharmacodynamic responses to chronic administration of the selective serotonin reuptake inhibitor citalopram in rats.
Wikell C; Apelqvist G; Carlsson B; Hjorth S; Bergqvist PB; Kugelberg FC; Ahlner J; Bengtsson F
Clin Neuropharmacol; 1999; 22(6):327-36. PubMed ID: 10626092
[TBL] [Abstract][Full Text] [Related]
6. Sustained citalopram treatment in experimental hepatic encephalopathy: effects on entrainment to the light-dark cycle and melatonin.
Kugelberg FC; Apelqvist G; Carlsson B; Ahlner J; Bengtsson F
Basic Clin Pharmacol Toxicol; 2006 Jul; 99(1):80-8. PubMed ID: 16867175
[TBL] [Abstract][Full Text] [Related]
7. Effect of halving the dose of venlafaxine to adjust for putative pharmacokinetic and pharmacodynamic changes in an animal model of chronic hepatic encephalopathy.
Wikell C; Kugelberg FC; Hjorth S; Apelqvist G; Bengtsson F
Clin Neuropharmacol; 2001; 24(6):324-33. PubMed ID: 11801807
[TBL] [Abstract][Full Text] [Related]
8. Potassium-evoked neuronal release of serotonin in experimental chronic portal-systemic encephalopathy.
Bergqvist PB; Hjorth S; Apelqvist G; Bengtsson F
Metab Brain Dis; 1997 Sep; 12(3):193-202. PubMed ID: 9346468
[TBL] [Abstract][Full Text] [Related]
9. Acute effects of L-tryptophan on brain extracellular 5-HT and 5-HIAA levels in chronic experimental portal-systemic encephalopathy.
Bergqvist PB; Hjorth S; Apelqvist G; Bengtsson F
Metab Brain Dis; 1996 Sep; 11(3):269-78. PubMed ID: 8869946
[TBL] [Abstract][Full Text] [Related]
10. In vivo steady-state pharmacokinetic outcome following clinical and toxic doses of racemic citalopram to rats.
Kugelberg FC; Apelqvist G; Carlsson B; Ahlner J; Bengtsson F
Br J Pharmacol; 2001 Apr; 132(8):1683-90. PubMed ID: 11309239
[TBL] [Abstract][Full Text] [Related]
11. Effects on drug disposition, brain monoamines and behavior after chronic treatment with the antidepressant venlafaxine in rats with experimental hepatic encephalopathy.
Wikell C; Apelqvist G; Hjorth S; Kullingsjö J; Bergqvist PB; Bengtsson F
Eur Neuropsychopharmacol; 2002 Aug; 12(4):327-36. PubMed ID: 12126872
[TBL] [Abstract][Full Text] [Related]
12. Stereoselective biotransformation of the selective serotonin reuptake inhibitor citalopram and its demethylated metabolites by monoamine oxidases in human liver.
Rochat B; Kosel M; Boss G; Testa B; Gillet M; Baumann P
Biochem Pharmacol; 1998 Jul; 56(1):15-23. PubMed ID: 9698084
[TBL] [Abstract][Full Text] [Related]
13. Stereoselective single-dose kinetics of citalopram and its metabolites in rats.
Kugelberg FC; Carlsson B; Ahlner J; Bengtsson F
Chirality; 2003 Aug; 15(7):622-9. PubMed ID: 12840828
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetic consequences of a citalopram treatment discontinuation.
Voirol P; Rubin C; Bryois C; Kosel M; Buclin T; Baumann P
Ther Drug Monit; 1999 Jun; 21(3):263-6. PubMed ID: 10365634
[TBL] [Abstract][Full Text] [Related]
15. Postmortem redistribution of the enantiomers of citalopram and its metabolites: an experimental study in rats.
Kugelberg FC; Druid H; Carlsson B; Ahlner J; Bengtsson F
J Anal Toxicol; 2004; 28(8):631-7. PubMed ID: 15538956
[TBL] [Abstract][Full Text] [Related]
16. Serotonin-2C antagonism augments the effect of citalopram on serotonin and dopamine levels in the ventral tegmental area and nucleus accumbens.
Visser AK; Kleijn J; van Faassen MH; Dremencov E; Flik G; Kema IP; Den Boer JA; van Waarde A; Dierckx RA; Bosker FJ
Neurochem Int; 2015 Feb; 81():10-5. PubMed ID: 25542858
[TBL] [Abstract][Full Text] [Related]
17. Neocortical dialysate monoamines of rats after acute, subacute, and chronic liver shunt.
Bergqvist PB; Vogels BA; Bosman DK; Maas MA; Hjorth S; Chamuleau RA; Bengtsson F
J Neurochem; 1995 Mar; 64(3):1238-44. PubMed ID: 7532208
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic drug monitoring of racemic citalopram: a 5-year experience in Sweden, 1992-1997.
Reis M; Lundmark J; Bengtsson F
Ther Drug Monit; 2003 Apr; 25(2):183-91. PubMed ID: 12657912
[TBL] [Abstract][Full Text] [Related]
19. p-Chloroamphetamine- and d-fenfluramine-induced brain serotonin release in experimental portal-systemic encephalopathy.
Bergqvist PB; Hjorth S; Wikell C; Apelqvist G; Bengtsson F
Metab Brain Dis; 1997 Sep; 12(3):229-36. PubMed ID: 9346471
[TBL] [Abstract][Full Text] [Related]
20. Ammonium acetate challenge in experimental chronic hepatic encephalopathy induces a transient increase of brain 5-HT release in vivo.
Bergqvist PB; Hjorth S; Audet RM; Apelqvist G; Bengtsson F; Butterworth RF
Eur Neuropsychopharmacol; 1996 Nov; 6(4):317-22. PubMed ID: 8985716
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
